Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a price target of $15, down from $47. The firm has removed cibotercept for pulmonary arterial hypertension from the ...

Matt Bryson, Wedbush analyst, joins 'Squawk on the Street' to discuss the state of the semiconductor industry.

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 “should be an inflection year” for Rocket with multiple ...

Investing.com -- Wedbush upgraded PulteGroup Inc (NYSE:PHM) to "outperform" from "neutral" given an overdone stock price decline and strong catalysts for growth. Shares were up 2.1% at $110.

Wedbush initiated coverage of Xometry (XMTR) with an Outperform rating and $48 price target Xometry is the leading digital marketplace for custom manufacturing and operates in a “large and ...

Wedbush added Wingstop (WING) to the firm’s Best Ideas List. The firm views Wingstop as well-positioned to deliver mid-single digit same-store sales growth in 2025 given its attractive value ...